These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 19848437)

  • 1. Cerebrolysin: a review of its use in dementia.
    Plosker GL; Gauthier S
    Drugs Aging; 2009; 26(11):893-915. PubMed ID: 19848437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spotlight on cerebrolysin in dementia.
    Plosker GL; Gauthier S
    CNS Drugs; 2010 Mar; 24(3):263-6. PubMed ID: 20155999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia.
    Allegri RF; Guekht A
    Drugs Today (Barc); 2012 Apr; 48 Suppl A():25-41. PubMed ID: 22514793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial.
    Guekht AB; Moessler H; Novak PH; Gusev EI;
    J Stroke Cerebrovasc Dis; 2011; 20(4):310-8. PubMed ID: 20656516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety profile of Cerebrolysin: clinical experience from dementia and stroke trials.
    Thome J; Doppler E
    Drugs Today (Barc); 2012 Apr; 48 Suppl A():63-9. PubMed ID: 22514795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrolysin in Alzheimer's disease.
    Antón Álvarez X; Fuentes P
    Drugs Today (Barc); 2011 Jul; 47(7):487-513. PubMed ID: 22013558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrolysin for vascular dementia.
    Chen N; Yang M; Guo J; Zhou M; Zhu C; He L
    Cochrane Database Syst Rev; 2013 Jan; (1):CD008900. PubMed ID: 23440834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with Cerebrolysin.
    Molloy DW; Standish TI
    J Neural Transm Suppl; 2000; 59():293-300. PubMed ID: 10961441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials.
    Gauthier S; Proaño JV; Jia J; Froelich L; Vester JC; Doppler E
    Dement Geriatr Cogn Disord; 2015; 39(5-6):332-47. PubMed ID: 25832905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin.
    Alvarez XA; Cacabelos R; Sampedro C; Aleixandre M; Linares C; Granizo E; Doppler E; Moessler H
    Eur J Neurol; 2011 Jan; 18(1):59-68. PubMed ID: 20500802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Memantine for dementia.
    Areosa SA; Sherriff F
    Cochrane Database Syst Rev; 2003; (3):CD003154. PubMed ID: 12917950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil.
    Alvarez XA; Cacabelos R; Sampedro C; Couceiro V; Aleixandre M; Vargas M; Linares C; Granizo E; García-Fantini M; Baurecht W; Doppler E; Moessler H
    Curr Alzheimer Res; 2011 Aug; 8(5):583-91. PubMed ID: 21679156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease.
    Bae CY; Cho CY; Cho K; Hoon Oh B; Choi KG; Lee HS; Jung SP; Kim DH; Lee S; Choi GD; Cho H; Lee H
    J Am Geriatr Soc; 2000 Dec; 48(12):1566-71. PubMed ID: 11129744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic results with Cerebrolysin in the treatment of dementia.
    Rainer M; Brunnbauer M; Dunky A; Ender F; Goldsteiner H; Holl O; Kotlan P; Paulitsch G; Reiner C; Stössl J; Zachhuber C; Mössler H
    Wien Med Wochenschr; 1997; 147(18):426-31. PubMed ID: 9408984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donepezil for vascular cognitive impairment.
    Malouf R; Birks J
    Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent.
    Panisset M; Gauthier S; Moessler H; Windisch M;
    J Neural Transm (Vienna); 2002 Jul; 109(7-8):1089-104. PubMed ID: 12111446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study.
    Muresanu DF; Alvarez XA; Moessler H; Novak PH; Stan A; Buzoianu A; Bajenaru O; Popescu BO
    J Neurol Sci; 2010 Dec; 299(1-2):179-83. PubMed ID: 20923712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galantamine for vascular cognitive impairment.
    Birks J; Craig D
    Cochrane Database Syst Rev; 2006 Jan; (4):CD004746. PubMed ID: 23862185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease.
    Wei ZH; He QB; Wang H; Su BH; Chen HZ
    J Neural Transm (Vienna); 2007; 114(5):629-34. PubMed ID: 17318304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nimodipine for primary degenerative, mixed and vascular dementia.
    López-Arrieta JM; Birks J
    Cochrane Database Syst Rev; 2002; (3):CD000147. PubMed ID: 12137606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.